Diagnostics company AutoGenomics is again trying its hand at going public, filing for a $65 million IPO and planning to trade under AGMX.
As Xconomy notes, AutoGenomics filed for an $86.3 million IPO back in 2008, but withdrew the offering in 2011. The company offers a suite of assays and diagnostic platforms, including its FDA-cleared Infiniti gene analyzer. In its filing with the SEC, AutoGenomics says it plans to put the prospective $65 million toward expanding its sales force and building up its marketing operation.
AutoGenomics reported $13 million in sales in the last fiscal year, and the company pulled in a $459,000 net profit on $8.7 million in revenue in the first 6 months of 2012, Xconomy reports.
The company offers about 50 tests for Infinity, including applications in personalized medicine, oncology and infectious disease. It has 15 tests under development, Xconomy notes, including assays for HPV and mutations in the cancer-related BRAF gene.